Grandview Asset Management LLC Boosts Stock Position in Eli Lilly and Company $LLY

Grandview Asset Management LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 3.4% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,417 shares of the company’s stock after buying an additional 46 shares during the quarter. Grandview Asset Management LLC’s holdings in Eli Lilly and Company were worth $1,105,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in LLY. WestEnd Advisors LLC grew its holdings in shares of Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares during the period. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter worth approximately $27,000. Citizens National Bank Trust Department grew its position in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after acquiring an additional 27 shares during the period. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the first quarter worth approximately $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% in the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after acquiring an additional 31 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently weighed in on LLY. Cantor Fitzgerald lowered their price target on Eli Lilly and Company from $975.00 to $825.00 and set an “overweight” rating for the company in a report on Wednesday, August 13th. Berenberg Bank reaffirmed a “hold” rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. Daiwa America lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Finally, Daiwa Capital Markets cut shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective for the company. in a research report on Sunday, August 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $939.61.

Insiders Place Their Bets

In related news, Director Jamere Jackson acquired 200 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the purchase, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Trading Up 1.4%

NYSE LLY opened at $724.73 on Friday. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00. The firm has a market cap of $685.93 billion, a price-to-earnings ratio of 47.37, a PEG ratio of 1.01 and a beta of 0.47. The firm has a 50 day simple moving average of $734.15 and a 200-day simple moving average of $766.82.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, beating the consensus estimate of $5.59 by $0.72. The company had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm’s revenue was up 37.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.